Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval
By Michael Susin
Johnson & Johnson said the Canadian health authority issued a notice of compliance for its lung-cancer treatment, meaning the drug is authorized to be marketed under certain conditions.
The pharmaceutical group said Health Canada approved the use of its asset Rybrevant, in combination with chemotherapy, for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor Exon 20 insertion mutations.
The notice of compliance is based on results from a late-stage study, which demonstrated a clinically meaningful and statistically significant improvement in progression-free survival and a 60% reduction in the risk of disease progression or death compared to chemotherapy alone.
"This approval reinforces our commitment to developing novel therapies, particularly for underserved patient populations with significant unmet needs," Janssen Inc.'s President Berkeley Vincent said. Janssen Inc. is a Johnson & Johnson company.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
July 03, 2024 08:43 ET (12:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now